Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise
On Friday, Novartis AG (NYSE:NVS) shared final results from the Phase 3 ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia (atrasentan).
IgAN (Berger's disease) is a chronic autoimmune kidney disease caused by the buildup of immunoglobulin A (IgA) protein in the glomeruli, causing inflammation and reducing the kidneys’ ability to filter waste.
Vanrafia received accelerated approval in the U.S. and China for the reduction of proteinuria in adults with IgAN in April 2025. After the trial data, Novartis plans to submit for traditional approval in 2026.
In April 2025, the company said it had not been established whether Vanrafia slows kidney function decline in patients with IgAN.
The continued approval of Vanrafia was contingent upon verifying clinical benefit from the ongoing Phase 3 ALIGN study evaluating whether Vanrafia slows disease progression as measured by estimated glomerular filtration rate (eGFR) decline at week 136.
Novartis Vanrafia Phase III Data Support Slowing Of Kidney Function Decline
On Friday, Vanrafia showed a difference of 2.39 ml/min/1.73m2 in estimated glomerular filtration rate (eGFR) change from baseline vs. placebo (2-sided p = 0.057) at Week 136, 4 weeks after the end of study treatment.
Clinically meaningful results were observed with Vanrafia compared to placebo in eGFR change from baseline at the end of study treatment at Week 132, and in the prespecified exploratory group of patients additionally receiving sodium-glucose co-transporter-2 (SGLT2) inhibitors.
At the end of treatment at Week 132, the eGFR change from baseline compared to placebo was 2.59 ml/min/1.73 m2.
The company on Friday said that ALIGN provides the longest follow-up period in pivotal Phase 3 studies for IgAN. Safety was consistent with previous findings.
Alongside Vanrafia, Novartis continues to advance its multi-asset IgAN portfolio, which also includes Fabhalta (iptacopan) and investigational compound zigakibart.
NVS Price Action: Novartis shares were up 0.42% at $161.86 during premarket trading on Friday. The stock is trading near its 52-week high of $162.31.
Photo via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"Agent vs US Treasury" — Who Will Dominate the US Stock Market?
The wave of AI Agents and US Treasury yields are splitting the US stock market into two worlds: Meta's release of the Muse model boosted its market value by $220 billion in a single week, propelling the Nasdaq's standout performance; however, excluding AI stocks, the S&P 500 actually fell 1% this week, with the number of new lows on the New York Stock Exchange surpassing new highs for nine consecutive days, signaling the near end of "breadth trading." Goldman Sachs bluntly stated that this is a "frustrating cat-and-mouse game" between the stock market and interest rates—any breakout can be snuffed out by the bond market at any time, so equity holders must short US Treasury bonds to hedge simultaneously.
Hopes for a ceasefire between the US and Iran encounter obstacles again! Trump rejects Iran's seven-day proposal; inflation pressure under $100 oil prices remains difficult to ease
Trump rejects a ceasefire with Iran, and it is expected that bombings will occur again after the midterm elections. The president doubts whether Tehran will meet his demands.
Tesla ramps Optimus production 10-fold but robot hands are holding Elon back
The More Impressive AI Agents Become, the More Valuable Storage Is! SK Hynix's NAND Business Plans $100 Billion US IPO
According to informed sources, Solidigm, a company under SK Hynix, is considering an initial public offering in the United States as early as next year. The sources revealed that the world's second-largest memory manufacturer is in talks with potential advisors regarding the listing of its NAND memory division.
Crypto prices
More
